Business Context and Reporting Period
This Form 8-K, filed on March 11, 2025, reports on a Special Meeting of Stockholders held by Coherus BioSciences, Inc. (CHRS) to vote on the approval of an Asset Purchase Agreement with Intas Pharmaceuticals Ltd. The agreement involves the divestiture of the Company's UDENYCA® (pegfilgrastim-cbqv) franchise.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the results of a shareholder vote regarding a corporate transaction.
Material Changes and Transaction Details
- Transaction Approval: Stockholders approved the sale of the UDENYCA® franchise to Intas Pharmaceuticals Ltd., a deal originally entered into on December 2, 2024.
- Voting Results: Out of 115,890,186 shares outstanding, 72,579,487 shares were voted. The proposal required 57,945,094 affirmative votes to pass.
- Vote Breakdown:
- For: 70,989,067
- Against: 968,989
- Abstain: 621,431
- Non-Votes: 0
Outlook, Risks, and Management Commentary
The filing confirms the successful completion of the shareholder approval process required to proceed with the divestiture. No specific financial guidance, risk factors, or management commentary regarding future performance is included in this specific report.
Key Facts for Investor Verification
- Verify the final closing date and specific financial terms (purchase price, earn-outs) of the UDENYCA® franchise sale to Intas Pharmaceuticals Ltd.
- Confirm the impact of this divestiture on Coherus BioSciences' future revenue streams and product portfolio.
- Review the Definitive Proxy Statement (Schedule 14A) filed on January 28, 2025, for detailed transaction rationale and related party disclosures.